Donald M O'rourke

List of Publications by Year
in descending order

131 papers	10,384 citations	38742 50 h-index	36028 97 g-index
133 all docs	133 docs citations	133 times ranked	14151 citing authors

#	Article	IF	Citations
1	IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature, 2012, 483, 474-478.	27.8	1,693
2	A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Science Translational Medicine, 2017, 9, .	12.4	1,116
3	Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncology, The, 2017, 18, 1373-1385.	10.7	776
4	A Patient-Derived Glioblastoma Organoid Model and Biobank Recapitulates Inter- and Intra-tumoral Heterogeneity. Cell, 2020, 180, 188-204.e22.	28.9	529
5	Imaging patterns predict patient survival and molecular subtype in glioblastoma via machine learning techniques. Neuro-Oncology, 2016, 18, 417-425.	1.2	243
6	Intraaxial Brain Masses: MR Imagingâ€“based Diagnostic Strategyâ€”Initial Experience. Radiology, 2007, 243, 539-550.	7.3	207
7	Sp1 Is Involved in Akt-mediated Induction of VEGF Expression through an HIF-1â€“independent Mechanism. Molecular Biology of the Cell, 2004, 15, 4841-4853.	2.1	206
8	CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges. Neuro-Oncology, 2018, 20, 1429-1438.	1.2	197
9	Vascular niche IL-6 induces alternative macrophage activation in glioblastoma through HIF-2Î±. Nature Communications, 2018, 9, 559.	12.8	176
10	Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo. Nature Biotechnology, 2000, 18, 194-198.	17.5	175
11	A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma. Clinical Cancer Research, 2019, 25, 5799-5807.	7.0	166
12	Grading of CNS neoplasms using continuous arterial spin labeled perfusion MR imaging at 3 Tesla. Journal of Magnetic Resonance Imaging, 2005, 22, 475-482.	3.4	156
13	The tyrosine phosphatase SHP-2 is required for mediating phosphatidylinositol 3-kinase/Akt activation by growth factors. Oncogene, 2001, 20, 6018-6025.	5.9	145
14	Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development. Cancer Cell, 2018, 34, 163-177.e7.	16.8	145
15	Differentiation between glioblastomas and solitary brain metastases using diffusion tensor imaging. NeuroImage, 2009, 44, 653-660.	4.2	141
16	Radiomic MRI signature reveals three distinct subtypes of glioblastoma with different clinical and molecular characteristics, offering prognostic value beyond IDH1. Scientific Reports, 2018, 8, 5087.	3.3	124
17	Checkpoint Blockade Reverses Anergy in IL-13RÎ±2 Humanized scFv-Based CAR T Cells to Treat Murine and Canine Gliomas. Molecular Therapy - Oncolytics, 2018, 11, 20-38.	4.4	123
18	PTEN mutation and epidermal growth factor receptor activation regulate vascular endothelial growth factor (VEGF) mRNA expression in human glioblastoma cells by transactivating the proximal VEGF promoter. Cancer Research, 2003, 63, 236-41.	0.9	120

#	Article	IF	Citations
19	Imaging Surrogates of Infiltration Obtained Via Multiparametric Imaging Pattern Analysis Predict Subsequent Location of Recurrence of Glioblastoma. Neurosurgery, 2016, 78, 572-580.	1.1	116
20	Immune landscapes associated with different glioblastoma molecular subtypes. Acta Neuropathologica Communications, 2019, 7, 203.	5.2	112
21	Constitutive EGFR signaling confers a motile phenotype to neural stem cells. Molecular and Cellular Neurosciences, 2003, 24, 1116-1130.	2.2	104
22	Activated EGFR signaling increases proliferation, survival, and migration and blocks neuronal differentiation in post-natal neural stem cells. Journal of Neuro-Oncology, 2010, 97, 323-337.	2.9	104
23	Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial. Clinical Cancer Research, 2020, 26, 1586-1594.	7.0	103
24	Expression of Oncogenic Epidermal Growth Factor Receptor Family Kinases Induces Paclitaxel Resistance and Alters Î²-Tubulin Isotype Expression. Journal of Biological Chemistry, 2000, 275, 17358-17363.	3.4	99
25	PDGF-mediated mesenchymal transformation renders endothelial resistance to anti-VEGF treatment in glioblastoma. Nature Communications, 2018, 9, 3439.	12.8	95
26	c-Metâ€“mediated endothelial plasticity drives aberrant vascularization and chemoresistance in glioblastoma. Journal of Clinical Investigation, 2016, 126, 1801-1814.	8.2	92
27	In vivoevaluation of EGFRvIII mutation in primary glioblastoma patients via complex multiparametric MRI signature. Neuro-Oncology, 2018, 20, 1068-1079.	1.2	90
28	Posttreatment Recurrence of Malignant Brain Neoplasm: Accuracy of Relative Cerebral Blood Volume Fraction in Discriminating Low from High Malignant Histologic Volume Fraction. Radiology, 2009, 250, 887-896.	7.3	86
29	Pattern Analysis of Dynamic Susceptibility Contrast-enhanced MR Imaging Demonstrates Peritumoral Tissue Heterogeneity. Radiology, 2014, 273, 502-510.	7.3	86
30	Wnt-mediated endothelial transformation into mesenchymal stem cellâ€“like cells induces chemoresistance in glioblastoma. Science Translational Medicine, 2020, 12, .	12.4	86
31	Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions. , 2020, 205, 107419.		81
32	In Vivo Detection of EGFRvIII in Glioblastoma via Perfusion Magnetic Resonance Imaging Signature Consistent with Deep Peritumoral Infiltration: The Ï•-Index. Clinical Cancer Research, 2017, 23, 4724-4734.	7.0	79
33	Circulating Glioma Cells Exhibit Stem Cell-like Properties. Cancer Research, 2018, 78, 6632-6642.	0.9	79
34	Autologous Heat Shock Protein Peptide Vaccination for Newly Diagnosed Glioblastoma: Impact of Peripheral PD-L1 Expression on Response to Therapy. Clinical Cancer Research, 2017, 23, 3575-3584.	7.0	78
35	Distinct Domains in the SHP-2 Phosphatase Differentially Regulate Epidermal Growth Factor Receptor/NF-ÎºB Activation through Gab1 in Glioblastoma Cells. Molecular and Cellular Biology, 2004, 24, 823-836.	2.3	68
36	Proton Magnetic Resonance Spectroscopy in Differentiating Glioblastomas From Primary Cerebral Lymphomas and Brain Metastases. Journal of Computer Assisted Tomography, 2010, 34, 836-841.	0.9	67

#	Article	IF	Citations
37	Use of magnetic perfusion-weighted imaging to determine epidermal growth factor receptor variant III expression in glioblastoma. Neuro-Oncology, 2012, 14, 613-623.	1.2	66
38	Experimental Traumatic Brain Injury Modulates the Survival, Migration, and Terminal Phenotype of Transplanted Epidermal Growth Factor Receptor-activated Neural Stem Cells. Neurosurgery, 2005, 56, 163-171.	1.1	63
39	Clinical Utility of Plasma Cell-Free DNA in Adult Patients with Newly Diagnosed Glioblastoma: A Pilot Prospective Study. Clinical Cancer Research, 2020, 26, 397-407.	7.0	63
40	Prediction of oligodendroglial tumor subtype and grade using perfusion weighted magnetic resonance imaging. Journal of Neurosurgery, 2007, 107, 600-609.	1.6	63
41	Role of monocyte chemoattractant proteinâ€1 (MCPâ€1/CCL2) in migration of neural progenitor cells toward glial tumors. Journal of Neuroscience Research, 2009, 87, 1547-1555.	2.9	61
42	Inhibition of EGFR-mediated phosphoinositide-3-OH kinase (PI3-K) signaling and glioblastoma phenotype by Signal-Regulatory Proteins (SIRPs). Oncogene, 2000, 19, 3999-4010.	5.9	60
43	Magnetic resonance perfusion-weighted imaging defines angiogenic subtypes of oligodendroglioma according to 1p19q and EGFR status. Journal of Neuro-Oncology, 2009, 92, 373-386.	2.9	60
44	Primary Cell Culture of Live Neurosurgically Resected Aged Adult Human Brain Cells and Single Cell Transcriptomics. Cell Reports, 2017, 18, 791-803.	6.4	60
45	Histopathologyâ€validated machine learning radiographic biomarker for noninvasive discrimination between true progression and pseudoâ€progression in glioblastoma. Cancer, 2020, 126, 2625-2636.	4.1	60
46	Neural Stem Cell Biology May Be Well Suited for Improving Brain Tumor Therapies. Cancer Journal (Sudbury, Mass), 2003, 9, 189-204.	2.0	58
47	Isoform-level gene signature improves prognostic stratification and accurately classifies glioblastoma subtypes. Nucleic Acids Research, 2014, 42, e64-e64.	14.5	57
48	Mitogenic Signaling Cascades in Glial Tumors. Neurosurgery, 2003, 52, 1425-1435.	1.1	56
49	Targeting PAK4 to reprogram the vascular microenvironment and improve CAR-T immunotherapy for glioblastoma. Nature Cancer, 2021, 2, 83-97.	13.2	56
50	Clinically silent somatotroph adenomas are common. European Journal of Endocrinology, 2011, 165, 39-44.	3.7	55
51	Inhibition of a naturally occurring EGFR oncoprotein by the p185neu ectodomain: implications for subdomain contributions to receptor assembly. Oncogene, 1998, 16, 1197-1207.	5.9	52
52	Receptor Tyrosine Kinase Signaling In Gliomagenesis: Pathobiology And Therapeutic Approaches. Cancer Biology and Therapy, 2003, 2, 330-342.	3.4	51
53	Population-based MRI atlases of spatial distribution are specific to patient and tumor characteristics in glioblastoma. NeuroImage: Clinical, 2016, 12, 34-40.	2.7	49
54	Pervasive within-Mitochondrion Single-Nucleotide Variant Heteroplasmy as Revealed by Single-Mitochondrion Sequencing. Cell Reports, 2017, 21, 2706-2713.	6.4	48

#	Article	IF	Citations
55	SHP-2-Dependent Mitogen-Activated Protein Kinase Activation Regulates EGFRvIII but not Wild-Type Epidermal Growth Factor Receptor Phosphorylation and Glioblastoma Cell Survival. Cancer Research, 2004, 64, 8292-8298.	0.9	42
56	The protein tyrosine phosphatase SHP-2 is required for EGFRvIII oncogenic transformation in human glioblastoma cells. Experimental Cell Research, 2009, 315, 2343-2357.	2.6	42
57	Automated Tumor Volumetry Using Computer-Aided Image Segmentation. Academic Radiology, 2015, 22, 653-661.	2.5	39
58	Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma. CNS Oncology, 2019, 8, CNS43.	3.0	38
59	Threeâ€dimensional echo planar spectroscopic imaging for differentiation of true progression from pseudoprogression in patients with glioblastoma. NMR in Biomedicine, 2019, 32, e4042.	2.8	38
60	Transcriptome signatures associated with meningioma progression. Acta Neuropathologica Communications, 2019, 7, 67.	5.2	36
61	Sustained Mitogen-Activated Protein Kinase Activation Is Induced by Transforming erbB Receptor Complexes. DNA and Cell Biology, 1999, 18, 731-741.	1.9	35
62	Symptomatic Lateral Ventricular Ependymal Cysts: Criteria for Distinguishing These Rare Cysts from Other Symptomatic Cysts of the Ventricles: Case Report. Neurosurgery, 2000, 46, 1229-1233.	1.1	35
63	Case Report: Prolonged Survival Following EGFRvIII CAR T Cell Treatment for Recurrent Glioblastoma. Frontiers in Oncology, 2021, 11, 669071.	2.8	34
64	Dominant Negative Form of Signal-regulatory Protein-Î± (SIRPÎ±/SHPS-1) Inhibits Tumor Necrosis Factor-mediated Apoptosis by Activation of NF-ÎºB. Journal of Biological Chemistry, 2003, 278, 3809-3815.	3.4	32
65	Locally secreted BiTEs complement CAR TÂcells by enhancing killing of antigen heterogeneous solid tumors. Molecular Therapy, 2022, 30, 2537-2553.	8.2	32
66	Mechanisms of resistance to CAR T cell therapies. Seminars in Cancer Biology, 2020, 65, 91-98.	9.6	31
67	AI-based prognostic imaging biomarkers for precision neuro-oncology: the ReSPOND consortium. Neuro-Oncology, 2020, 22, 886-888.	1.2	31
68	Role of Proton Magnetic Resonance Spectroscopy in Differentiating Oligodendrogliomas from Astrocytomas. Journal of Neuroimaging, 2010, 20, 3-8.	2.0	30
69	Domain-specific Interactions between the p185 and Epidermal Growth Factor Receptor Kinases Determine Differential Signaling Outcomes. Journal of Biological Chemistry, 1999, 274, 574-583.	3.4	29
70	Sprouty2 Drives Drug Resistance and Proliferation in Glioblastoma. Molecular Cancer Research, 2015, 13, 1227-1237.	3.4	29
71	SHP2 regulates proliferation and tumorigenicity of glioma stem cells. Journal of Neuro-Oncology, 2017, 135, 487-496.	2.9	29
72	Gene silencing for epidermal growth factor receptor variant III induces cell-specific cytotoxicity. Molecular Cancer Therapeutics, 2008, 7, 3586-3597.	4.1	28

#	Article	IF	Citations
73	Multiparametric magnetic resonance imaging in the assessment of anti-EGFRvIII chimeric antigen receptor T cell therapy in patients with recurrent glioblastoma. British Journal of Cancer, 2019, 120, 54-56.	6.4	27
74	Potential of Glioblastoma-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy. CNS Drugs, 2020, 34, 127-145.	5.9	26
75	Cancer Imaging Phenomics via CaPTk: Multi-Institutional Prediction of Progression-Free Survival and Pattern of Recurrence in Glioblastoma. JCO Clinical Cancer Informatics, 2020, 4, 234-244.	2.1	26
76	Relationship of p215BRCA1 to tyrosine kinase signaling pathways and the cell cycle in normal and transformed cells. Oncogene, 1997, 14, 2863-2869.	5.9	25
77	Actinomycotic brain infection: registered diffusion, perfusion MR imaging and MR spectroscopy. Neuroradiology, 2006, 48, 346-350.	2.2	25
78	Absence of autophosphorylation site Y882 in the p185neu oncogene product correlates with a reduction of transforming potential. Oncogene, 1998, 16, 2835-2842.	5.9	24
79	Treatment of steroid refractory, Gamma Knife related radiation necrosis with bevacizumab: Case report and review of the literature. Clinical Neurology and Neurosurgery, 2011, 113, 798-802.	1.4	21
80	Molecular Neuropathology in Practice: Clinical Profiling and Integrative Analysis of Molecular Alterations in Glioblastoma. Academic Pathology, 2019, 6, 2374289519848353.	1.1	21
81	Factors Associated with Increased Survival after Surgical Resection of Glioblastoma in Octogenarians. PLoS ONE, 2015, 10, e0127202.	2.5	20
82	Clinical measures, radiomics, and genomics offer synergistic value in AI-based prediction of overall survival in patients with glioblastoma. Scientific Reports, 2022, 12, .	3.3	20
83	Intracranial control after Cyberknife radiosurgery to the resection bed for large brain metastases. Radiation Oncology, 2015, 10, 221.	2.7	19
84	The LACE+ index fails to predict 30â€“90 day readmission for supratentorial craniotomy patients: A retrospective series of 238 surgical procedures. Clinical Neurology and Neurosurgery, 2019, 182, 79-83.	1.4	17
85	Differentiation of brain infection from necrotic glioblastoma using combined analysis of diffusion and perfusion MRI. Journal of Magnetic Resonance Imaging, 2019, 49, 184-194.	3.4	17
86	The application of 5-bromodeoxyuridine in the management of CNS tumors. Journal of Neuro-Oncology, 1994, 20, 81-95.	2.9	16
87	The Ability of Protein Tyrosine Phosphatase SHP-1 to Suppress NFÎºB Can Be Inhibited by Dominant Negative Mutant of SIRPÎ±. DNA and Cell Biology, 2004, 23, 175-182.	1.9	16
88	LACE+ Index as Predictor of 30-Day Readmission in Brain Tumor Population. World Neurosurgery, 2019, 127, e443-e448.	1.3	16
89	Detection of occult neoplastic infiltration in the corpus callosum and prediction of overall survival in patients with glioblastoma using diffusion tensor imaging. European Journal of Radiology, 2019, 112, 106-111.	2.6	16
90	Association of dynamic susceptibility contrast enhanced MR Perfusion parameters with prognosis in elderly patients with glioblastomas. European Radiology, 2015, 25, 2738-2744.	4.5	15

#	Article	IF	Citations
91	Histopathologic quantification of viable tumor versus treatment effect in surgically resected recurrent glioblastoma. Journal of Neuro-Oncology, 2019, 141, 421-429.	2.9	15
92	Imaging and histopathologic correlates of plasma cell-free DNA concentration and circulating tumor DNA in adult patients with newly diagnosed glioblastoma. Neuro-Oncology Advances, 2020, 2, vdaa016.	0.7	15
93	Risk of intracranial hemorrhage with direct oral anticoagulants vs low molecular weight heparin in glioblastoma: A retrospective cohort study. Neuro-Oncology, 2022, 24, 2172-2179.	1.2	15
94	Anticancer effects of fenretinide in human medulloblastoma. Cancer Letters, 2006, 231, 262-269.	7.2	14
95	18F-Fluciclovine PET to distinguish treatment-related effects from disease progression in recurrent glioblastoma: PET fusion with MRI guides neurosurgical sampling. Neuro-Oncology Practice, 2020, 7, 152-157.	1.6	14
96	High-Affinity Chimeric Antigen Receptor With Cross-Reactive scFv to Clinically Relevant EGFR Oncogenic Isoforms. Frontiers in Oncology, 2021, 11, 664236.	2.8	14
97	Resident training in neurosurgical oncology: results of the survey of North American training programs by the AANS/CNS Section on Tumors. Journal of Neuro-Oncology, 2006, 77, 241-246.	2.9	13
98	Multi-institutional noninvasive in vivo characterization of IDH, 1p/19q, and EGFRvIII in glioma using neuro-Cancer Imaging Phenomics Toolkit (neuro-CaPTk). Neuro-Oncology Advances, 2020, 2, iv22-iv34.	0.7	12
99	EGFR inhibition in glioblastoma cells induces G2/M arrest and is independent of p53. Cancer Biology and Therapy, 2007, 6, 571-579.	3.4	10
100	Novel risk scores for survival and intracranial failure in patients treated with radiosurgery alone to melanoma brain metastases. Radiation Oncology, 2015, 10, 248.	2.7	10
101	Arterial Spin Labeling and Dynamic Susceptibility Contrast-enhanced MR Imaging for evaluation of arteriovenous shunting and tumor hypoxia in glioblastoma. Scientific Reports, 2019, 9, 8747.	3.3	10
102	Quantification of tumor microenvironment acidity in glioblastoma using principal component analysis of dynamic susceptibility contrast enhanced MR imaging. Scientific Reports, 2021, 11, 15011.	3.3	10
103	Association of plasma cell-free DNA with survival in patients with IDH wild-type glioblastoma. Neuro-Oncology Advances, 2021, 3, vdab011.	0.7	10
104	Engineering Chimeric Antigen Receptor T cells to Treat Glioblastoma. The Journal of Targeted Therapies in Cancer, 2017, 6, 22-25.	2.0	10
105	PD1 Expression in EGFRvIII-Directed CAR T Cell Infusion Product for Glioblastoma Is Associated with Clinical Response. Frontiers in Immunology, 2022, 13, .	4.8	10
106	Glioblastoma: The Current State of Biology and Therapeutic Strategies. Cancer Research, 2022, 82, 769-772.	0.9	9
107	Immunologic Features in De Novo and Recurrent Glioblastoma Are Associated with Survival Outcomes. Cancer Immunology Research, 2022, 10, 800-810.	3.4	9
108	Transcriptional Regulation of Signal Regulatory Protein Î±1 Inhibitory Receptors by Epidermal Growth Factor Receptor Signaling. Cancer Research, 2004, 64, 6444-6452.	0.9	7

#	Article	IF	Citations
109	Negative prognostic impact of epidermal growth factor receptor copy number gain in young adults with isocitrate dehydrogenase wild-type glioblastoma. Journal of Neuro-Oncology, 2019, 145, 321-328.	2.9	7
110	Molecular and Clinical Characterization of UBE2S in Glioma as a Biomarker for Poor Prognosis and Resistance to Chemo-Radiotherapy. Frontiers in Oncology, 2021, 11, 640910.	2.8	7
111	Enhancing CAR T function with the engineered secretion of C.Âperfringens neuraminidase. Molecular Therapy, 2022, 30, 1201-1214.	8.2	7
112	Identification of pl85^{neu}Sequences Required for Monoclonal Antibody- or Ligand-Mediated Receptor Signal Attenuation. DNA and Cell Biology, 1997, 16, 1395-1405.	1.9	6
113	An additive score optimized by a genetic learning algorithm predicts readmission risk after glioblastoma resection. Journal of Clinical Neuroscience, 2020, 80, 1-5.	1.5	6
114	Type V Dural Arteriovenous Fistula Supplied by the Artery of Wollschlaeger and Wollschlaeger Causing Cervical Myelopathy and Quadriparesis. World Neurosurgery, 2020, 137, 55-61.	1.3	6
115	Evaluating the Association Between the Extent of Resection and Survival in Gliosarcoma. Cureus, 2019, 11, e4374.	0.5	6
116	NIMG-05IDENTIFICATION OF IMAGING SIGNATURES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III (EGFRvIII) IN GLIOBLASTOMA. Neuro-Oncology, 2015, 17, v154.1-v154.	1.2	5
117	Go, no-go decision making for phase 3 clinical trials: ACT IV revisited â€“ Authors' reply. Lancet Oncology, The, 2017, 18, e709-e710.	10.7	5
118	Multivariate Analysis of Preoperative Magnetic Resonance Imaging Reveals Transcriptomic Classification of de novo Glioblastoma Patients. Frontiers in Computational Neuroscience, 2019, 13, 81.	2.1	5
119	Rapid and ultrasensitive digital PCR (dPCR) profiling of EGFRvIII in tumor cells and tissues. Neuro-Oncology Advances, 2019, 1, vdz030.	0.7	5
120	RNA-seq for identification of therapeutically targetable determinants of immune activation in human glioblastoma. Journal of Neuro-Oncology, 2019, 141, 95-102.	2.9	5
121	A dual-genotype oligoastrocytoma with histologic, molecular, radiological and time-course features. Acta Neuropathologica Communications, 2020, 8, 115.	5.2	5
122	Immunotherapy and Response Assessment in Malignant Glioma. Topics in Magnetic Resonance Imaging, 2020, 29, 95-102.	1.2	5
123	Reversion of the ErbB malignant phenotype and the DNA damage response. Experimental and Molecular Pathology, 2012, 93, 324-333.	2.1	4
124	Assignment Confidence in Localization of the Hand Motor Cortex: Comparison of Structural Imaging With Functional MRI. American Journal of Roentgenology, 2016, 207, 1263-1270.	2.2	3
125	CAR T Cells. Neurosurgery Clinics of North America, 2021, 32, 249-263.	1.7	3
126	Identification of a 140 kDa protein of rat presynaptic terminal membranes encompassing the active zones. Brain Research, 1995, 700, 261-270.	2.2	2

#	Article	IF	Citations
127	MR susceptibility imaging for detection of tumor-associated macrophages inÂglioblastoma. Journal of Neuro-Oncology, 2022, 156, 645-653.	2.9	2
128	General Principles of Immunotherapy for Glioblastoma. , 2016, , 237-246.		1
129	Use of targeted next generation sequencing (NGS) to assess mutational load in glioblastoma (GBM).. Journal of Clinical Oncology, 2017, 35, 2027-2027.	1.6	1
130	Risk of intracranial hemorrhage with direct oral anticoagulants versus low molecular weight heparin in glioblastoma: A retrospective cohort study.. Journal of Clinical Oncology, 2022, 40, 2015-2015.	1.6	1
131	Abstract 2203: Identifying the transcriptomic signatures of mutational heterogeneity in GBM using single cell genomics. , 2021, , .		0